Strand Life Sciences, a subsidiary of Reliance Industries, has launched the Somatic Advantage 74 Liquid Biopsy (SA74 LB) Test, a tool designed to detect circulating tumour DNA in the blood of cancer patients.
In a press statement on Tuesday, the company informed that the SA74 LB Test offers a comprehensive analysis of 74 clinically significant genes, providing critical insights to guide cancer treatment decisions.
With over 24 years of experience and more than 50,000 genetic tests conducted, Strand Life Sciences is leveraging its expertise to offer a test known for its high accuracy and sensitivity. The SA74 LB Test uses Unique Molecular Identifiers (UMIs) to ensure precise detection of genetic variations, helping identify important biomarkers that influence cancer therapies. The company’s lab, accredited by both CAP and NABL, maintains strict adherence to international quality standards.
Key features of the SA74 LB Test include:
Actionable Insights: It covers genomic alterations in 74 clinically relevant genes associated with therapy recommendations in line with FDA and NCCN guidelines.
High Reliability: The UMI-based library preparation delivers high analytical sensitivity.
Deep Coverage: Pre-UMI coverage of over 15,000x and post-UMI coverage of over 2,000x ensures comprehensive genetic analysis.
Minimally Invasive: A simple blood sample is all that’s required, offering a convenient and non-invasive option for patients.
The SA74 LB Test presents multiple advantages over traditional tissue biopsy methods. Its non-invasive nature and ability to assess genetic variability across multiple tumour sites make it particularly valuable for patients whose tumours are inaccessible or when biopsy tissue quality is insufficient. By delivering timely and precise genetic data, the test helps doctors optimise treatment plans, ultimately improving patient outcomes.
Dr. Ramesh Hariharan, CEO of Strand Life Sciences, commented, "We are excited to introduce the SA74 LB Test as part of our Somatic Advantage portfolio. This liquid biopsy test will make genetic testing more accessible and actionable for patients. Strand Life Sciences is dedicated to innovation in precision medicine, empowering healthcare professionals to provide personalised care. The launch of this test underscores our commitment to advancing cancer diagnostics and improving patient lives.”
